Vaginal CO2 Laser Therapy for Genitourinary Syndrome in Breast Cancer Survivors

This project will be based on three studies over a period on three years. The first study is a dose response study that includes 30 breast cancer survivors. They will receive a total of 5 laser treatments with 4-6 weeks intervals The second study is a double-blind randomized controlled trial, that includes 60 breast cancer survivors. 30 of those will receive active intervention and 30 will receive placebo laser treatment and act as controls. Based on the results of the dose response study, a treatment consists of three to five laser treatments every 3 weeks. The third and last study is a one-y

Trial Details

NCT ID

NCT06007027

Phase

Sponsor

University of Aarhus

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

SmartXIDE2V2LR, Monalisa Touch, DEKA, Florence, Italy

Locations (sample)

Randers, Denmark|56.4607,10.03639

Key Eligibility Criteria

Breast cancer survivor in endocrine therapy
Symptomatic genitourinary symdrom of menopause with vaginal discomfort and/or dyspareunia
Able to read and understand Danish
Able to give written informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →